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Background: To evaluate the clinical presentation of pregnant women in Iran who 
died due to COVID-19.
Methods: Data were evaluated of pregnant women who died following a laboratory 
diagnosis of COVID-19. The data were obtained from electronic medical records. 
Additionally, a questionnaire was completed for each patient, including demographic, 
clinical, laboratorial, imaging, and treatment data. In case of missing information, a 
member of the research team contacted the first-degree relatives via phone.
Results: Of 32 pregnant women who tested positive for COVID-19, 15 were enrolled 
into the study (mean age 30.0 ± 5.0 years). The mean time from first symptoms to 
death was 12 ± 7.0 days. Pre-existing comorbidities were seen in six patients. The 
main presentations at admission were fatigue and coughing, but most of the women 
had a fever below 38 °C. Increased white blood cell count and neutrophils were no-
ticeable. A significant drop of saturation of O2 with ground glass and consolidation 
seen in both lungs were prominent. The most common complications were acute res-
piratory distress syndrome followed by respiratory failure.
Conclusion: Computed tomography findings, O2 pressure, and regular blood assess-
ment may be considered suitable indicators for the surveillance of patients.
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1  |  INTRODUC TION
COVID-19 was introduced in December 2019 as a new member of 
the beta coronavirus family. The virus very quickly became an en-
demic infection. Hence, its transmission is not a simple issue and the 
potential modes of transmission need to be considered. Moreover, 
despite the virus affecting mainly the respiratory system, other vital 
organs can also be seriously affected.1,2 Therefore, a broad spectrum 
of presentation in this situation can be assumed. The mortality rate 
of COVID-19 is reported to be in the range of 2%–16%, depending on 
age. Furthermore, the rate of mortality may increase two- to ten-fold 
among patients admitted to the intensive care unit (ICU) with pre-ex-
isting morbidities such as cardiovascular disease and diabetes.1,3 Li 
et al.3 reported that the mortality rate of patients with hypertension, 
cerebrovascular diseases, and diabetes was two- to three-fold higher 
in patients admitted to the ICU, respectively. The main risk factors 
of mortality are older age, shortness of breath or dyspnea, low level 
of hemoglobin, and underlying comorbidities. Several clinical out-
comes such as respiratory failure, acute respiratory distress syndrome 
(ARDS), septic shock, coagulopathy, acute cardiac injury, and acute kid-
ney injury are significantly higher in non-survivor patients. However, 
pregnant women as a particular group may be different.4,5
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In a normal pregnancy, it has been shown that according to phys-
iological changes, a mother's susceptibility to microorganisms (bacte-
ria and viruses) and their products increases.6 It has been proven that 
pregnant women are at risk for H1N1 as well as severe acute respi-
ratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), 
and Ebola infection.7 Nevertheless, during the COVID-19 pandemic, 
the fatality rate of pregnant women is not well-known and the effect 
of this novel virus on the maternal state is unclear. It is assumed that 
pregnant women are no more likely to get the disease than the gen-
eral population.8-10 Previous studies revealed that the virus might not 
lead to an increased fatality rate during pregnancy.8,11 In a Swedish 
report, the risk of being admitted to the ICU was higher in infected 
pregnant and postpartum women than non-pregnant women of simi-
lar ages.12 Furthermore, in a study of 116 pregnant women in China,13 
the authors concluded that COVID-19 had no effect on pregnancy 
outcomes. However, there are not many studies regarding non-survi-
vor pregnant patients. The aim of the present study was to illustrate 
the characteristics of pregnant patients who died in order to identify 
early critically ill patients with COVID-19 and reduce their mortality.
2  |  METHODS
2.1  |  Patients
In the present retrospective study, out of 32 pregnant women with 
COVID-19, the medical files were reviewed for 15 non-survivors 
who were hospitalized between March 2020 and June 2020 and 
who died in hospital. The patients were admitted to Firoozgar 
General Hospital, Iran; a tertiary hospital which has been as-
signed as one of the referral hospitals for patients with COVID-
19. COVID-19 was confirmed in the laboratory according to WHO 
guidelines (the detection of virus RNA was considered a confirmed 
positive result).
2.2  |  Collection of data
A questionnaire was completed, including demographic, clinical 
presentation, laboratory, and imaging data. All data were obtained 
from the electronic files of each patient. In case of any missing data, 
a member of the team contacted the first-degree relatives of the 
patient.
2.3  |  Laboratory data
All laboratory tests were carried out by the team according to WHO 
guidelines.14
A venous blood sample was obtained from each patient on the 
first day of admission. Laboratory items were analyzed using di-
agnostic kits (Pars Azmoon Co., Iran) and Auto-Analyzer BS200 
(Mindray, Nanshan, Shenzhen, China).
For the extraction of virus RNA, a nasopharyngeal swab technique 
was used. Then, a one-step real-time polymerase chain reaction was 
performed by a referral diagnostic laboratory. In addition, all patients 
underwent a standard chest computed tomography (CT) scan. The 
protocol was approved by the Ethics Committee of Firoozgar Hospital.
2.4  |  Statistical analysis
The mean ± SD is presented for normal and non-normal continuous 
variables, respectively. Normal distribution was checked using the 
Shapiro–Wilk test. Categorical variables were expressed as number 
(percentage). All statistical analyses were carried out using SPSS ver-
sion 20.0 (IBM Corp., Armonk, NY, USA).
3  |  RESULTS
Overall, 15 pregnant patients who died due to COVID-19 were en-
rolled. The deaths occurred in the same period of hospitalization. 
The mean age of the women was 30.0 ± 5.0 years, the mean time 
of hospitalization was 5.0 ± 3.0 days, and the mean time from first 
symptoms to death was 12 ± 7.0 days.
Pre-existing comorbidities were seen in six patients: three pa-
tients had diabetes mellitus, of whom one had gestational diabetes 
(Table 1). Interestingly, the majority of patients had a fever below 
38°C. As illustrated in Table 2, the main presentations at admission 
were fatigue, coughing, and myalgia in 11, 10, and five patients, 
TA B L E  1  Basic characteristics of non-survivor pregnant 
patientsa
Variable Total (n = 15)
Length of stay in hospital (days) 5.0 ± 3.0
Time from first symptoms to admission (days) 6.00 ± 5.07
Time from first symptoms to death (days) 12 ± 7.0





Cardiovascular disease 1 (6.6)
Lung disease 0 (0)
Diabetes 3 (19.8)
Renal disease 0 (0)
Liver disease 0 (0)
Neurologic disease 0 (0)
Cancer 0 (0)
Uses of immunosuppressive drugs 0 (0)
aValues are given as number (percentage) or mean ± SD. 
bComorbidities: Diabetes mellitus or gestational diabetes, 
cardiovascular disease, and hypertension. 
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respectively. A respiratory rate of more than 24 breaths per minute 
was also seen in eight patients. The laboratory results at the time of 
admission are shown in Table 3. It can be seen that increased white 
blood cell count (WBC) was common among these women. Hence, a 
WBC more than 10 × 109/L was seen in 9 (70%) patients. Although 
neutrophilia was prominent, lymphopenia was not a common find-
ing and was seen in only four patients. Furthermore, there was no 
decrease in the levels of hemoglobin or platelets in these patients. 
Liver function tests, including ALT, AST, and alkaline phosphates, 
were in the normal ranges in the majority of the pregnant women.
The main finding in the assessment of atrial blood gas was 
a significant drop in the saturation of O2. In addition, during an 
evaluation by CT scan, almost all patients had a ground-glass view 
in both lungs, and in 11 patients, consolidation was seen in both 
sides (Table 4). Furthermore, the most common complications 
were ARDS and respiratory failure in seven and four patients, re-
spectively (Table 5).
4  |  DISCUSSION
The present study is a large study regarding non-survivor pregnant 
patients with COVID-19 in Iran. In the present case series, it was 
observed that the primary manifestation was a sore throat followed 
TA B L E  2  Clinical findings of non-survivor pregnant patientsa





Sore throat 3 (19.8)
Headache 4 (26.4)
Chest pain 4 (26.4)
Coughing 10 (66)





Shortness of breath 3 (19.8)
Dizziness 2 (13.2)
Nausea and vomiting 4 (26.4)
Abdominal pain 2 (13.2)
Diarrhea 1 (6.6)
Respiratory rate (≥24 breaths per min) 8 (52.8)
Pulse rate (≥120 bpm) 3 (19.8)
CURB score
2 vs 0–1 2 (13.2)
≥3 vs 0–1 3 (19.8)
aValues are given as number (percentage). 
TA B L E  3  The laboratory findings of non-survivor pregnant 
patientsa
Variables (normal range) Total (n = 15)




Neutrophil (1.8–7.4 × 109/L) 7.90 ± 1.0
<7000 4 (26.6)
≥7000 11 (73.4)
Lymphocyte (1.0–4.4 × 109/L) 1.47 ± 0.8
<1000 4 (26.6)
≥1000 11 (73.4)
Platelets (150–400 × 109/L) 171.50 ± 10
>150 000 10 (66.7)
100 000–150 000 1 (6.6)
<100 000 4 (26.6)
Hemoglobin (12–16 g/dL) 11.50 ± 1.8
<10 3 (20)
≥10 12 (80)
Sodium (135–148 mmol/L) 136.12 ± 4.1
<135 5 (33.3)
≥135 10 (66.7)
Potassium (3.5–5.3 mmol/L) 3.8 ± 0.65
<4 12 (80)
≥4 3 (20)
Blood urea nitrogen (7–20 mg/dL) 35.4 ± 6.5
<20 11 (73.4)
≥20 4 (26.6)
Creatinine (0.6–1.4 mg/dL) 0.9 ± 0.2
<1.3 14 (93.4)
≥1.3 1 (6.6)
Total bilirubin (0.1–1.1 mg/dL) 1.10 ± 0.7
<1.7 9 (60)
≥1.7 3 (20)
No. checked 3 (20)
Direct bilirubin (<0.4 mg/dL) 1.0 ± 1.1
<0.5 7 (46.7)
≥0.5 5 (33.3)
No. checked 3 (20)
Alanine transferase (15–40 IU/L) 30.0 ± 20.0
<40 11 (73.4)
≥40 3 (20)
No. checked 1 (6.6)
Aspartate amino transferase (15–40 IU/L) 27.0 ± 20.0
<40 11 (73.4)
≥40 3 (20)
No. checked 1 (6.6)
(Continues)
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by chest pain. High-grade fever was not common. Interestingly, high 
levels of WBC and neutrophil count, as well as the presence of con-
solidation on CT evaluation, were ordinary.
According to the results of the present study, the patients were 
referred to the study center during the last days of their pregnancy 
for delivery. Hence, they were probably infected in the last month 
of their pregnancy. In addition, the main clinical presentations were 
similar to those of general patients with COVID-19. Moreover, the 
length of hospitalization before death was not longer than that of 
the general population. This finding is consistent with previous re-
ports.5,11,15 On the other hand, while older age can be considered a 
risk factor for worse outcomes in COVID-19 infection,16 the patients 
were young; therefore, the possible effect of age might not be signif-
icant. Pre-existing comorbidities are a critical issue that need more 
consideration. Seven patients in the study group had pre-existing 
comorbidities. Gestational diabetes was seen in one patient. In a 
previous study, pre-existing comorbidities, particularly hypertension 
and diabetes, were associated with worse outcomes.
The issue that may need more consideration despite recent ep-
idemiologic studies is the transmission of the virus. As the patients 
explained, almost all of them had no contact with other patients 
with COVID-19 during the previous few weeks before developing 
symptoms of COVID-19. This may be related to the state of emer-
gency at the time of admission, where history taking was not opti-
mal. On other hand, the unknown viral infection with the potential 
of spreading is not well understood. Hence, its diagnosis and pre-
vention become more difficult. Moreover, the nosocomial transmis-
sion of the disease may occur mainly during the incubation period 
and by close contact with patients with minimal symptoms.1,17
It is also not clear whether pregnant women are more prone 
to contracting COVID-19 compared to the general population, al-
though previous studies have stated that pregnant women are prone 
to infection due to their “immunosuppressed” state.18,19 The risk of 
developing severe symptoms of COVID-19 during pregnancy is not 
clear20; it seems that symptoms tend to be less severe than those of 
a typical influenza infection.21
In the present study, the main complication was respiratory compli-
cations presenting as ARDS and respiratory failure. Furthermore, the 
duration between the first symptoms and death was about 12 days, 
and they were usually admitted to hospital after 1 week, showing the 
aggressive and violent nature of the virus in these patients. The results 
consist of previous reports of ultrasound findings.22 In fact, COVID-
19 can cause multiorgan damage. In previous reports, cardiovascular 
damage is considered at the top of the list of organ damage in patients 
with COVID-19.2,23 However, respiratory side effects were common 
in the present series, consistent with previous studies including preg-
nant patients.24 Furthermore, cardiac and kidney complications must 
be observed. The patients in the present study were not evaluated 
regularly for cardiac events. Therefore, cardiac events during hospi-
talization cannot be confirmed. In fact, the heart may be the target of 
pulmonary viral infection, either directly or indirectly. The mechanism 
of organ damage by COVID-19 has not been well understood; It may 
be related to inflammation pathways and cytokine storms.2,4
Variables (normal range) Total (n = 15)
Alkaline phosphatase (98–279 U/L) 244.0 ± 130
<280 9 (60.1)
≥280 4 (26.6)
No. checked 2 (13.3)
SPO2 (>93%) 78.34 ± 16.46
<90 15 (100)
≥90 0 (0)
pH (7.36–7.44) 7.2 ± 0.1
<7.4 8 (53.4)
≥7.4 3 (20)
No. checked 4 (26.6)
CO2 (36–44 mm Hg) 36.0 ± 2.0
<40 5 (33.3)
≥40 6 (40.1)
No. checked 4 (26.6)
HCO3 (21–27 nmol/L) 22.80 ± 5.0
<24 6 (40.1)
≥24 5 (33.3)
No. checked 4 (26.6)
aValues are given as number (percentage) or mean ± SD. 
TA B L E  3  (Continued)
TA B L E  4  Computed tomography findings among non-survivor 
pregnant patientsa
Variables Total (n = 15)
Patchy consolidation on both sides 11 (73.4)
Ground glass
One side 3 (20)
Both sides 11 (73.4)
Patchy infiltration
One side 2 (13.2)
Both sides 13 (86.8)
aValues are given as number (percentage). 
TA B L E  5  The complications of COVID-19 infection among non-
survival pregnant patientsa
Variables Total (n = 15)
Sepsis 1 (6.6)
Respiratory failure 4 (26.6)
ARDS 7 (46)
Septic shock 0 (0)
Coagulopathy 2 (13)
Acute kidney injury 1 (6.6)
Acute cardiac injury 2 (13)
Acidosis 2 (13)
Abbreviation: ARDS, acute respiratory distress syndrome.
aValues are given as number (percentage). 
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Regarding prognostic laboratory parameters, in the present 
study, the other factor that may be associated with worsening of 
patient outcomes was neutrophilia (>7.7 × 109/L). Furthermore, a 
decrease in levels of lymphocytes and hemoglobin among patients 
was not observed. Neutrophilia may be associated with acute car-
diac events and the development of sepsis, which can increase the 
odds of mortality. Indeed, a decrease in the level of hemoglobin 
is associated with poor outcomes and mortality in a previous re-
port.25 Previous studies reported the critical value of the complete 
blood count differential, including the levels of lymphocytes and 
neutrophils as well as hemoglobin, with the patient outcomes.26
In conclusion, a pregnant patient is probably at the same risk of 
developing severe COVID-19 as the general population. The time 
between admission and death is not long and this needs more atten-
tion. It seems that low O2 saturation, along with consolidation in CT 
scanning and neutrophilia at admission, can predict worse outcomes.
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